Benzodiazepine Withdrawal Syndrome. Adverse effect of benzodiazepines
Conditions
Interventions
Intervention 1: Control group: patients in this group are given placebo 2 times a day for 2 weeks-The placebos are the exact physical replica of Levetiracetam tablets manufactured by Abidi Pharmaceuti
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients who had been taking Benzodiazepines for at least three months, and have not discontinued them for more than one month.
Exclusion criteria
Exclusion criteria: Patients diagnosed with acute and major psychological disorders, schizophrenia, epilepsy, or concurrent neurological disorders, e.g. Multiple Sclerosis Patients with a history of taking Levetiracetam or receiving concurrent Gabapentin or Carbamazepine in the last six months Patients younger than 15 years of age Allergic reactions to Levetiracetam or its excipients Severe adverse drug reactions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sum of Scores for CIWA-B Questionnaire. Timepoint: At benzodiazepine cessation and before taking Levetiracetam, then 2 weeks after taking Levetiracetam. Method of measurement: CIWA-B Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSheida Javid
Tehran University of Medical Sciences
Outcome results
None listed